Medscape1d
Upadacitinib Dosing for AD Can Be Increased or Decreased Depending on Response
A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...
Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data
Immunovant's batoclimab showed positive Phase 3 results in MG but won't be pursued for approval as the company shifts focus ...
The Print on MSN2d
Fat-busting drug Mounjaro launched in India. Here’s how much it will cost
US pharma giant Eli Lilly's Mounjaro can prove crucial in treatment of obesity & type 2 diabetes. Launched in the US in 2022, ...
Medscape2d
Real-World Study Reveals Early Success of Upadacitinib in Atopic Dermatitis Control
Upadacitinib demonstrates early and sustained effectiveness up to 1 year in patients with moderate to severe atopic dermatitis in a real-world study.
Business Wire1mon
Amneal Launches Mesalamine and Receives U.S. FDA Approval for Lenalidomide
10 mg, 15 mg, 20 mg, and 25 mg strengths. In settlement of all outstanding claims related to this product, Celgene agreed to provide Amneal with a license to Celgene’s patents required to ...